Naseem Muhammad, Ullah Safi, Alizai Qaidar, Motie Ali
Neuro-Rehab, Somerset NHS Foundation Trust, Taunton, GBR.
General Medicine, eSHIFA, Shifa Integrated Healthcare Technologies (Private) Limited, Islamabad, PAK.
Cureus. 2024 Jun 28;16(6):e63411. doi: 10.7759/cureus.63411. eCollection 2024 Jun.
This case report details the case of a 70-year-old man with Marfan syndrome and hypertension who developed neutropenia after an eight-week course of ceftriaxone, used to treat a brain abscess. Initially presenting with tonic-clonic seizures and headaches, his condition was managed with ceftriaxone and metronidazole. The subsequent drop in neutrophil counts from 7.54 × 10^9/L to 0.87 × 10^9/L leads to the discontinuation of ceftriaxone and the administration of granulocyte-colony stimulating factor (G-CSF), which effectively restored the neutrophil levels. This case highlights that clinicians should be aware of ceftriaxone-induced neutropenia as a potential complication, especially in patients undergoing prolonged therapy. Regular monitoring and timely management are essential for patient safety and favorable outcomes.
本病例报告详细介绍了一名患有马凡综合征和高血压的70岁男性患者的情况,该患者在使用头孢曲松治疗脑脓肿八周后出现了中性粒细胞减少症。他最初表现为强直阵挛性癫痫发作和头痛,病情通过头孢曲松和甲硝唑进行治疗。随后中性粒细胞计数从7.54×10^9/L降至0.87×10^9/L,导致头孢曲松停药,并给予粒细胞集落刺激因子(G-CSF),这有效地恢复了中性粒细胞水平。该病例强调,临床医生应意识到头孢曲松诱导的中性粒细胞减少症是一种潜在并发症,尤其是在接受长期治疗的患者中。定期监测和及时处理对于患者安全和良好预后至关重要。